1VRTX Stock Overview

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details

1VRTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 48.6% below our estimate of its fair value

Earnings are forecast to grow 31.06% per year

Risk Analysis

No risks detected for 1VRTX from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Vertex Pharmaceuticals Incorporated Competitors

Philogen

BIT:PHIL

€878.3m

Amgen

NasdaqGS:AMGN

US$143.0b

Gilead Sciences

NasdaqGS:GILD

US$120.5b

CSL

ASX:CSL

AU$115.9b

Price History & Performance

Summary of share price highs, lows and changes for Vertex Pharmaceuticals
Historical stock prices
Current Share Price	US$382.45
52 Week High	US$487.60
52 Week Low	US$380.00
Beta	0.51
1 Month Change	-8.89%
3 Month Change	-16.05%
1 Year Change	-2.11%
3 Year Change	63.41%
5 Year Change	46.20%
Change since IPO	93.61%

Recent updates

Shareholder Returns

	1VRTX	IT Biotechs	IT Market
7D	-13.1%	-7.6%	2.5%
1Y	-2.1%	-1.1%	12.9%

Return vs Industry: 1VRTX underperformed the Italian Biotechs industry which returned -1.1% over the past year.

Return vs Market: 1VRTX underperformed the Italian Market which returned 12.9% over the past year.

Price Volatility

Is 1VRTX's price volatile compared to industry and market?
1VRTX volatility
1VRTX Average Weekly Movement	5.0%
Biotechs Industry Average Movement	8.5%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1VRTX has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1VRTX's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1989	6,100	Reshma Kewalramani	www.vrtx.com

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.

Vertex Pharmaceuticals Incorporated Fundamentals Summary

How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap?
1VRTX fundamental statistics
Market cap	€96.98b
Earnings (TTM)	-€878.74m
Revenue (TTM)	€9.86b

9.8x

P/S Ratio

-110.4x

P/E Ratio

Is 1VRTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1VRTX income statement (TTM)
Revenue	US$11.10b
Cost of Revenue	US$5.21b
Gross Profit	US$5.89b
Other Expenses	US$6.88b
Earnings	-US$988.90m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.85
Gross Margin	53.09%
Net Profit Margin	-8.91%
Debt/Equity Ratio	0%

How did 1VRTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 12:10
End of Day Share Price	2025/05/09 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vertex Pharmaceuticals Incorporated is covered by 66 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Vertex Pharmaceuticals BIT:1VRTX Stock Report